Protective and herapeutic capacity of human single-chain Fv-Fc fusion proteins against West Nile virus

L. Hannah Gould, Jianhua Sui, Harald Foellmer, Theodore Oliphant, Tian Wang, Michel Ledizet, Akikazu Murakami, Kristin Noonan, Cassandra Lambeth, Kalipada Kar, John F. Anderson, Aravinda M. De Silva, Michael S. Diamond, Raymond A. Koski, Wayne A. Marasco, Erol Fikrig

Research output: Contribution to journalArticle

97 Citations (Scopus)

Abstract

West Nile virus has spread rapidly across the United States, and there is currently no approved human vaccine or therapy to prevent or treat disease. Passive immunization with antibodies against the envelope protein represents a promising means to provide short-term prophylaxis and treatment for West Nile virus infection. In this study, we identified a panel of 11 unique human single-chain variable region antibody fragments (scFvs) that bind the envelope protein of West Nile virus. Selected scFvs were converted to Fc fusion proteins (scFv-Fcs) and were tested in mice for their ability to prevent lethal West Nile virus infection. Five of these scFv-Fcs, 11, 15, 71, 85, and 95, protected 100% of mice from death when given prior to infection with virus. Two of them, 11 and 15, protected 80% of mice when given at days 1 and 4 after infection. In addition, four of the scFv-Fcs cross-neutralized dengue virus, serotype 2. Binding assays using yeast surface display demonstrated that all of our scFvs bind to sites within domains I and II of West Nile virus envelope protein. These recombinant human scFvs are potential candidates for immunoprophylaxis and therapy of flavivirus infections.

Original languageEnglish (US)
Pages (from-to)14606-14613
Number of pages8
JournalJournal of Virology
Volume79
Issue number23
DOIs
StatePublished - Dec 2005
Externally publishedYes

Fingerprint

Single-Chain Antibodies
West Nile virus
Virus Diseases
infection
Proteins
proteins
mice
Flavivirus Infections
Viral Envelope Proteins
Flavivirus
Active Immunotherapy
Dengue virus
therapeutics
Dengue Virus
antibodies
Passive Immunization
immunization
disease control
Yeasts
vaccines

ASJC Scopus subject areas

  • Immunology

Cite this

Protective and herapeutic capacity of human single-chain Fv-Fc fusion proteins against West Nile virus. / Gould, L. Hannah; Sui, Jianhua; Foellmer, Harald; Oliphant, Theodore; Wang, Tian; Ledizet, Michel; Murakami, Akikazu; Noonan, Kristin; Lambeth, Cassandra; Kar, Kalipada; Anderson, John F.; De Silva, Aravinda M.; Diamond, Michael S.; Koski, Raymond A.; Marasco, Wayne A.; Fikrig, Erol.

In: Journal of Virology, Vol. 79, No. 23, 12.2005, p. 14606-14613.

Research output: Contribution to journalArticle

Gould, LH, Sui, J, Foellmer, H, Oliphant, T, Wang, T, Ledizet, M, Murakami, A, Noonan, K, Lambeth, C, Kar, K, Anderson, JF, De Silva, AM, Diamond, MS, Koski, RA, Marasco, WA & Fikrig, E 2005, 'Protective and herapeutic capacity of human single-chain Fv-Fc fusion proteins against West Nile virus', Journal of Virology, vol. 79, no. 23, pp. 14606-14613. https://doi.org/10.1128/JVI.79.23.14606-14613.2005
Gould, L. Hannah ; Sui, Jianhua ; Foellmer, Harald ; Oliphant, Theodore ; Wang, Tian ; Ledizet, Michel ; Murakami, Akikazu ; Noonan, Kristin ; Lambeth, Cassandra ; Kar, Kalipada ; Anderson, John F. ; De Silva, Aravinda M. ; Diamond, Michael S. ; Koski, Raymond A. ; Marasco, Wayne A. ; Fikrig, Erol. / Protective and herapeutic capacity of human single-chain Fv-Fc fusion proteins against West Nile virus. In: Journal of Virology. 2005 ; Vol. 79, No. 23. pp. 14606-14613.
@article{49a42116f5f14510bb7825865aaa1ce1,
title = "Protective and herapeutic capacity of human single-chain Fv-Fc fusion proteins against West Nile virus",
abstract = "West Nile virus has spread rapidly across the United States, and there is currently no approved human vaccine or therapy to prevent or treat disease. Passive immunization with antibodies against the envelope protein represents a promising means to provide short-term prophylaxis and treatment for West Nile virus infection. In this study, we identified a panel of 11 unique human single-chain variable region antibody fragments (scFvs) that bind the envelope protein of West Nile virus. Selected scFvs were converted to Fc fusion proteins (scFv-Fcs) and were tested in mice for their ability to prevent lethal West Nile virus infection. Five of these scFv-Fcs, 11, 15, 71, 85, and 95, protected 100{\%} of mice from death when given prior to infection with virus. Two of them, 11 and 15, protected 80{\%} of mice when given at days 1 and 4 after infection. In addition, four of the scFv-Fcs cross-neutralized dengue virus, serotype 2. Binding assays using yeast surface display demonstrated that all of our scFvs bind to sites within domains I and II of West Nile virus envelope protein. These recombinant human scFvs are potential candidates for immunoprophylaxis and therapy of flavivirus infections.",
author = "Gould, {L. Hannah} and Jianhua Sui and Harald Foellmer and Theodore Oliphant and Tian Wang and Michel Ledizet and Akikazu Murakami and Kristin Noonan and Cassandra Lambeth and Kalipada Kar and Anderson, {John F.} and {De Silva}, {Aravinda M.} and Diamond, {Michael S.} and Koski, {Raymond A.} and Marasco, {Wayne A.} and Erol Fikrig",
year = "2005",
month = "12",
doi = "10.1128/JVI.79.23.14606-14613.2005",
language = "English (US)",
volume = "79",
pages = "14606--14613",
journal = "Journal of Virology",
issn = "0022-538X",
publisher = "American Society for Microbiology",
number = "23",

}

TY - JOUR

T1 - Protective and herapeutic capacity of human single-chain Fv-Fc fusion proteins against West Nile virus

AU - Gould, L. Hannah

AU - Sui, Jianhua

AU - Foellmer, Harald

AU - Oliphant, Theodore

AU - Wang, Tian

AU - Ledizet, Michel

AU - Murakami, Akikazu

AU - Noonan, Kristin

AU - Lambeth, Cassandra

AU - Kar, Kalipada

AU - Anderson, John F.

AU - De Silva, Aravinda M.

AU - Diamond, Michael S.

AU - Koski, Raymond A.

AU - Marasco, Wayne A.

AU - Fikrig, Erol

PY - 2005/12

Y1 - 2005/12

N2 - West Nile virus has spread rapidly across the United States, and there is currently no approved human vaccine or therapy to prevent or treat disease. Passive immunization with antibodies against the envelope protein represents a promising means to provide short-term prophylaxis and treatment for West Nile virus infection. In this study, we identified a panel of 11 unique human single-chain variable region antibody fragments (scFvs) that bind the envelope protein of West Nile virus. Selected scFvs were converted to Fc fusion proteins (scFv-Fcs) and were tested in mice for their ability to prevent lethal West Nile virus infection. Five of these scFv-Fcs, 11, 15, 71, 85, and 95, protected 100% of mice from death when given prior to infection with virus. Two of them, 11 and 15, protected 80% of mice when given at days 1 and 4 after infection. In addition, four of the scFv-Fcs cross-neutralized dengue virus, serotype 2. Binding assays using yeast surface display demonstrated that all of our scFvs bind to sites within domains I and II of West Nile virus envelope protein. These recombinant human scFvs are potential candidates for immunoprophylaxis and therapy of flavivirus infections.

AB - West Nile virus has spread rapidly across the United States, and there is currently no approved human vaccine or therapy to prevent or treat disease. Passive immunization with antibodies against the envelope protein represents a promising means to provide short-term prophylaxis and treatment for West Nile virus infection. In this study, we identified a panel of 11 unique human single-chain variable region antibody fragments (scFvs) that bind the envelope protein of West Nile virus. Selected scFvs were converted to Fc fusion proteins (scFv-Fcs) and were tested in mice for their ability to prevent lethal West Nile virus infection. Five of these scFv-Fcs, 11, 15, 71, 85, and 95, protected 100% of mice from death when given prior to infection with virus. Two of them, 11 and 15, protected 80% of mice when given at days 1 and 4 after infection. In addition, four of the scFv-Fcs cross-neutralized dengue virus, serotype 2. Binding assays using yeast surface display demonstrated that all of our scFvs bind to sites within domains I and II of West Nile virus envelope protein. These recombinant human scFvs are potential candidates for immunoprophylaxis and therapy of flavivirus infections.

UR - http://www.scopus.com/inward/record.url?scp=27744601405&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27744601405&partnerID=8YFLogxK

U2 - 10.1128/JVI.79.23.14606-14613.2005

DO - 10.1128/JVI.79.23.14606-14613.2005

M3 - Article

VL - 79

SP - 14606

EP - 14613

JO - Journal of Virology

JF - Journal of Virology

SN - 0022-538X

IS - 23

ER -